[
  {
    "nct_id": "NCT05671001",
    "molecule": "CardioFlow-7",
    "title": "Safety and Efficacy of CardioFlow-7 in Severe Hypertension",
    "phase": "Phase 2",
    "status": "Completed",
    "condition": "Hypertension",
    "start_date": "2021-03-10",
    "end_date": "2022-08-15",
    "results_summary": "Primary endpoint met. Significant reduction in systolic BP vs placebo. Mild dizziness reported in 5% of subjects.",
    "sponsor": "Global Pharma Corp",
    "region": "North America"
  },
  {
    "nct_id": "NCT05671002",
    "molecule": "CardioFlow-7",
    "title": "Long-term Cardiovascular Outcomes of CardioFlow-7",
    "phase": "Phase 3",
    "status": "Recruiting",
    "condition": "Hypertension",
    "start_date": "2023-01-05",
    "end_date": "2025-12-01",
    "results_summary": null,
    "sponsor": "Global Pharma Corp",
    "region": "Europe"
  },
  {
    "nct_id": "NCT05671003",
    "molecule": "CardioFlow-7",
    "title": "Exploratory Study of CardioFlow-7 for Migraine Prevention",
    "phase": "Phase 1/2",
    "status": "Completed",
    "condition": "Migraine",
    "start_date": "2022-06-01",
    "end_date": "2023-01-20",
    "results_summary": "Unexpected reduction in migraine frequency observed in hypertensive patients. Further investigation recommended.",
    "sponsor": "University Medical Center",
    "region": "North America"
  },
  {
    "nct_id": "NCT05671004",
    "molecule": "CardioFlow-7",
    "title": "CardioFlow-7 in Pediatric Hypertension",
    "phase": "Phase 1",
    "status": "Terminated",
    "condition": "Hypertension",
    "start_date": "2022-09-01",
    "end_date": "2022-11-15",
    "results_summary": "Study terminated early due to poor enrollment. No safety concerns identified.",
    "sponsor": "Global Pharma Corp",
    "region": "North America"
  },
  {
    "nct_id": "NCT09982001",
    "molecule": "NeuroZ-12",
    "title": "Efficacy of NeuroZ-12 in Refractory Epilepsy",
    "phase": "Phase 3",
    "status": "Completed",
    "condition": "Epilepsy",
    "start_date": "2019-04-12",
    "end_date": "2021-05-30",
    "results_summary": "Highly effective in reducing seizure frequency (45% reduction). FDA approved for adjunctive therapy.",
    "sponsor": "NeuroTech Solutions",
    "region": "Global"
  },
  {
    "nct_id": "NCT09982002",
    "molecule": "NeuroZ-12",
    "title": "NeuroZ-12 for Management of Diabetic Neuropathy Pain",
    "phase": "Phase 2",
    "status": "Completed",
    "condition": "Neuropathic Pain",
    "start_date": "2022-02-10",
    "end_date": "2023-03-15",
    "results_summary": "Significant pain reduction scores on VAS scale compared to placebo. Side effect profile acceptable.",
    "sponsor": "NeuroTech Solutions",
    "region": "Europe"
  },
  {
    "nct_id": "NCT09982003",
    "molecule": "NeuroZ-12",
    "title": "Study of NeuroZ-12 in Generalized Anxiety Disorder",
    "phase": "Phase 2",
    "status": "Recruiting",
    "condition": "Anxiety",
    "start_date": "2023-08-01",
    "end_date": "2024-12-01",
    "results_summary": null,
    "sponsor": "BioHealth Institute",
    "region": "Asia-Pacific"
  },
  {
    "nct_id": "NCT09982004",
    "molecule": "NeuroZ-12",
    "title": "Dosing Study of NeuroZ-12 in Elderly Patients",
    "phase": "Phase 1",
    "status": "Completed",
    "condition": "Healthy Volunteers",
    "start_date": "2018-01-10",
    "end_date": "2018-06-01",
    "results_summary": "Pharmacokinetics indicate lower clearance in elderly. Dose adjustment required.",
    "sponsor": "NeuroTech Solutions",
    "region": "Europe"
  },
  {
    "nct_id": "NCT01113001",
    "molecule": "Immuno-X",
    "title": "Immuno-X for Moderate to Severe Rheumatoid Arthritis",
    "phase": "Phase 3",
    "status": "Completed",
    "condition": "Rheumatoid Arthritis",
    "start_date": "2020-01-15",
    "end_date": "2022-02-28",
    "results_summary": "Standard of care efficacy met. Non-inferior to Humira.",
    "sponsor": "Apex Biologics",
    "region": "North America"
  },
  {
    "nct_id": "NCT01113002",
    "molecule": "Immuno-X",
    "title": "Immuno-X in Crohn's Disease Maintenance",
    "phase": "Phase 2",
    "status": "Active, not recruiting",
    "condition": "Crohn's Disease",
    "start_date": "2022-05-10",
    "end_date": "2024-05-10",
    "results_summary": "Interim analysis shows promising mucosal healing rates.",
    "sponsor": "Apex Biologics",
    "region": "Europe"
  },
  {
    "nct_id": "NCT01113003",
    "molecule": "Immuno-X",
    "title": "Topical Immuno-X for Psoriasis Plaques",
    "phase": "Phase 1/2",
    "status": "Suspended",
    "condition": "Psoriasis",
    "start_date": "2023-01-01",
    "end_date": "2023-06-01",
    "results_summary": "Suspended due to formulation stability issues. No safety events in patients.",
    "sponsor": "Dermatology Partners",
    "region": "Asia-Pacific"
  },
  {
    "nct_id": "NCT01113004",
    "molecule": "Immuno-X",
    "title": "Immuno-X for Systemic Lupus Erythematosus (SLE)",
    "phase": "Phase 2",
    "status": "Withdrawn",
    "condition": "Systemic Lupus Erythematosus",
    "start_date": "2021-11-01",
    "end_date": "2021-12-01",
    "results_summary": "Withdrawn prior to enrollment due to strategic business decision.",
    "sponsor": "Apex Biologics",
    "region": "North America"
  }
]